EMA Details Trial Misconduct Behind Tavneos EU Revocation

Company: Amgen · Event Type: Regulatory Action (Negative) · Product/Asset: Avacopan (Tavneos) · EU Revocation Decision: August 6, 2026 · EMA Reasoning Published: August 14, 2026 Summary The European Medicines Agency published its scientific reasoning for revoking the European marketing authorization of Amgen’s avacopan (Tavneos),…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK – $1B SiranBio Oligo Deal